Inspire Medical Systems, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About Leading the INSP Securities Class Action

Core Points - Inspire Medical Systems, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its Inspire V Device, which is intended for the treatment of obstructive sleep apnea [1][3] - The class period for the lawsuit is from August 6, 2024, to August 4, 2025 [1] Allegations - The Inspire V Device was marketed as a groundbreaking product with significant revenue potential, but the launch was poorly received, leading to excess inventory and reluctance from providers to adopt the new treatment [3][4] - Key operational failures were cited, including incomplete training for treatment centers, lack of necessary IT systems, and unpreparedness for insurance claims processing and Medicare reimbursement [4] Financial Impact - On August 4, 2025, Inspire disclosed that the launch of Inspire V would face an extended timeline due to undisclosed challenges, resulting in a drastic reduction of its 2025 earnings guidance by over 80%, from $2.20-$2.30 per share to $0.40-$0.50 per share [5] - Following this announcement, the stock price plummeted by $42.04, or more than 32%, from $129.95 to $87.91 per share, erasing $1.2 billion in market capitalization in a single day [5] - From a high of $216.71 per share on September 23, 2024, the stock price has decreased by $127.00, nearly 60%, resulting in billions lost in market capitalization [5]